Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.

Date publication

octobre 2020

Journal

JAMA network open

Auteurs

Membres identifiés du Cancéropôle Est :
Mme HENRIQUES Julie

Tous les auteurs :
Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33074326

Résumé

In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%, respectively, with adjuvant fluorouracil and oxaliplatin-based chemotherapy; however, the trial did not demonstrate a disease-free survival (DFS) benefit of adding bevacizumab to oxaliplatin-based chemotherapy in stage III CC and suggested a detrimental effect on OS. The Long-term Survival AVANT (S-AVANT) study was designed to collect extended follow-up for patients in the AVANT trial.

Mots clés

Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, therapeutic use, Capecitabine, therapeutic use, Chemotherapy, Adjuvant, Colonic Neoplasms, drug therapy, Disease-Free Survival, Female, Fluorouracil, therapeutic use, Humans, Leucovorin, therapeutic use, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds, therapeutic use, Oxaloacetates, therapeutic use, Proportional Hazards Models, Treatment Outcome

Référence

JAMA Netw Open. 2020 10 1;3(10):e2020425